Blend — no study of the combination; CJC-1295 has one small human pharmacology study, ipamorelin has animal data only
The blend pairs a GHRH analogue (CJC-1295, without DAC) with a ghrelin-receptor agonist (ipamorelin). Nobody has studied the two together. CJC-1295's only human data are a small pharmacokinetic study; ipamorelin has never been through a human trial. What can be said comes from those sources and from the known effects of raising growth hormone.
Research-use information only. Research-grade CJC-1295 / Ipamorelin Blend is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| CJC-1295 (component): headache, flushing, injection-site reactions | not quantified | Reported as transient and mild in the healthy-volunteer pharmacology study; no serious adverse events attributed to the drug. | Teichman et al. 2006 (n = ~50, single and multiple doses) |
| Ipamorelin (component) | not quantified | No human adverse-effect data; described as selective for GH release without cortisol/ACTH rise in animal work. | Raun et al. 1998 |
| Effects of raised GH / IGF-1 | not quantified | Water retention, joint aches and altered glucose handling are the known consequences of elevated GH exposure in general; not measured for this blend. | General GH pharmacology |
No study has evaluated this combination. The evidence lives with the components:
Regulatory status: Neither component is approved anywhere. Ipamorelin's development was discontinued; CJC-1295 development stopped after 2006.
Everything above describes CJC-1295 / Ipamorelin Blend the molecule. The risk specific to a research vial is different: it may not contain CJC-1295 / Ipamorelin Blend at the labelled amount, and it may contain what the synthesis left behind. Identity (mass spectrometry), purity (HPLC), measured net content and an endotoxin result are the four lines on a certificate that bear on adverse effects, and only a certificate you can check at the laboratory tells you any of them. This is what we have verified for CJC-1295 / Ipamorelin Blend so far.
11 of the 77 vendors on our scoreboard list CJC-1295 / Ipamorelin Blend with a price we read on the product page (23 Sept 2026–23 Sept 2026). Of those, 11 name their testing laboratory, 8 publish certificates that resolve on the lab's own site, and 10 publish measured milligrams against the label. The full ranking, with every dated price, is on Best CJC-1295 / Ipamorelin Blend Vendors.
| Vendor | Rubric | Lab named | Price read |
|---|---|---|---|
| Peptide Giantspartner | 10/10 | Janoshik Analytical · Vanguard Laboratory | $47.00 · 10mg · 23 Sept 2026 |
| Purgo Labspartner | 10/10 | SteriGenix · Freedom Diagnostics | $55.99 · 10mg · 23 Sept 2026 |
| Ameano Peptidespartner | 9/10 | Janoshik Analytical | $53.00 · 10mg · 23 Sept 2026 |
| Rivn Peptidespartner | 9/10 | Freedom Diagnostics | $64.99 · 10mg · 23 Sept 2026 |
| TrustedPepspartner | 9/10 | Freedom Diagnostics (on certificates) | $30.00 · 10mg · 23 Sept 2026 |
Top 5 by rubric score; 6 more on the ranking page.
None yet for CJC-1295 / Ipamorelin Blend specifically. The COA library holds the certificates we have read for each vendor on other compounds, which is the next best signal of how that vendor documents a lot.
No study has looked. CJC-1295 on its own caused transient headache, flushing and injection-site reactions in a small healthy-volunteer study; ipamorelin has no human data at all. Beyond that, the honest answer is the general profile of raising growth hormone — fluid retention, joint aches, glucose effects — none of it measured for this blend.